The evidence on diverse non-pharmacological therapies for managing AD is synthesized and their practical implications for clinical care are discussed to generate a broader and more lasting impact on disease treatment.
Abstract
Abstract Alzheimer's disease (AD) is a multifactorial neurodegenerative disease affecting various cognitive domains, requiring a holistic and integrated therapeutic approach. The treatment of AD goes beyond pharmacological interventions, also necessitating non-pharmacological therapies that can act synergistically, both with each other and with emerging pharmacological treatments, including new anti-amyloid therapies. These therapies aim to improve patients’ quality of life and alleviate behavioral symptoms, such as agitation and depression, and delay disease progression. Current clinical and meta-analytic evidence suggests that these approaches can be effectively integrated with conventional treatment, offering a valuable alternative to enhance patients’ overall well-being. However, further research is needed to deepen the understanding of the ideal combination of the new anti-amyloid therapies, to address the limitations of current evidence, and to robustly establish their effectiveness in the clinical context of AD, aiming to generate a broader and more lasting impact on disease treatment. This narrative review aims to synthesize the evidence on diverse non-pharmacological therapies for managing AD and discuss their practical implications for clinical care.
This review systematically synthesizes literature from the PubMed and Web of Science databases to evaluate the comparative efficacy of physical activity, dietary interventions, and cognitive stimulation therapy (CST), aiming to establish an evidence-based framework for optimized clinical implementation.
Jialin Chen, Ziyu Zhang· Frontiers in Aging Neuroscie...· 0 citations
Alzheimer’s Disease (AD) is a neurodegenerative disorder with
progressive cognitive decline, β-amyloid plaques, neurofibrillary tangles, oxidative stress,
and neuroinflammatory responses. So far, the pathogenesis of AD has been explained by
the cholinergic hypothesis, amyloid cascade hypothesis, and tau protein dys...
Lalit Parihar, A. Singh, Sanjar Alam· Current Pharmacogenomics and...· 0 citations
INTRODUCTION
Alzheimer's disease (AD) is the most common neurodegenerative dementia affecting millions globally. Therapies primarily consist of symptomatic management and progression limitation. Further advances in treatments include disease-modifying therapies, many of which have unfavorable safety profiles and modest...
Abarajithan Chandrasekaran, Alexandra Paget-Blanc, Boris Decourt et al.· Expert Opinion on Pharmacoth...· 0 citations
Alzheimer’s disease (AD) is a chronic, progressive neurodegenerative disorder and the leading cause of dementia worldwide, with prevalence increasing due to population aging. It is characterized by cognitive decline, functional impairment, and significant public health burden. Pathophysiology involves a complex interpl...
Mikołaj Jońca, Gabriela Majchrowicz, Natasza Kurys et al.· International Journal of Inn...· 0 citations
The synergistic pathological network between Aβ and tau is clarified, updated progress on targeted therapies are summarized, and theoretical support for accurate early diagnosis and individualized clinical treatment of AD is offered.
Kexin Liu· Theoretical and Natural Scie...· 0 citations
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, neuronal loss, and the accumulation of β-amyloid plaques and tau pathology. For many years, pharmacological treatment has been limited to symptomatic therapies, including acetylcholinesterase inhibitors and memantin...
Kacper Jaskulski, Katarzyna Kowalenko, J. Szadkowski et al.· International Journal of Inn...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.